Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders Of Walgreens Boots Alliance Inc Are Encouraged By The Schall Law Firm To Join The Probe Into Suspected Securities Fraud

AMC Entertainment

Big Lots

Almost every company has some debt. Many large and very profitable companies obtained significant amounts of debt when interest rates were negligible from 2009 until 2021.

Red Flags: 3 Stocks Drowning in Debt to Sell ASAP

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Walgreens securities between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). Investors have until September 10, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

WALGREENS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Walgreens Boots Alliance, Inc. and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $WBA #WBA--Robbins LLP is Investigating Allegations that Walgreens Boots Alliance, Inc. (WBA) Misled Investors Regarding its Business Prospects.

Walgreens Boots Alliance, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the WBA Class Action Lawsuit

Bank of Nova Scotia

Enbridge

Universal Corp

Vector Group

Xerox

24/7 Wall Street Insights An anticipated interest rate cut by the Federal Reserve to help the troubled real estate market will likely hike inflation further.

Want $5,000? Invest $10,000 in These 7 Dividend Stocks

SAN DIEGO, CA / ACCESSWIRE / July 17, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) securities between October 12, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v.

WBA INVESTOR ALERT: Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Walgreens cut its dividend this year, but it's still costing the company more than $860 million annually. Free cash flow has often been insufficient to cover the dividend payments.

Walgreens Doesn't Need to Cut Its Dividend, It Needs to Completely Suspend It

NEW YORK , July 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Shareholders that lost money on Walgreens Boots Alliance, Inc.(WBA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders Of Walgreens Boots Alliance Inc Are Urged By The Schall Law Firm To Participate In The Inquiry Into Alleged Securities Fraud

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 10, 2024 to file lead plaintiff applications in a securities class action lawsuit against Walgreens Boots Alliance, Inc. (NasdaqGS: WBA), if they purchased the Company's securities between October 12, 2023 to June 26, 2024, inclusive (the “Class Period”). This action is pending in the United States District.

WALGREENS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Walgreens Boots Alliance, Inc. - WBA

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens, the leading integrated independent retail pharmacy and healthcare provider, is launching Nice! For You, a new tier of its popular owned grocery brand, Nice!, to help customers find food choices that help support their journey to a healthier lifestyle. Nice! launched in 2011 and offers a range of everyday food and beverage products at an incredible value. While all Nice! products meet national brand standards of high-quality ingredients, Nice! For You.

Walgreens Introduces Nice! For You to Help Customers Make Healthier Food and Beverage Choices

Altria

Walgreens has thousands of pharmacies, but there isn't a lot it can do about increasingly unfavorable reimbursement rates for prescription drugs. Altria Group's Marlboro brand is still the most popular cigarette in America, but competition from an illicit e-cigarette market is a major challenge.

2 S&P 500 Dividend Stocks With Yields Above 8% That You Can Buy With $100 Right Now

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Walgreens Boots Alliance, Inc. (“Walgreens”) (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, inclusive (the “Class Period”). For more information, submit a form at Walgreens Boots Alliance, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.

WALGREENS BOOTS ALLIANCE, INC. (NASDAQ: WBA) INVESTOR ALERT: Investors With Large Losses in Walgreen Boots Alliance, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

LOS ANGELES , July 16, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

WBA Investors Have the Opportunity to Join Walgreens Boots Alliance, Inc. Securities Fraud Investigation with the Schall Law Firm

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024. Walgreens is a global company that delivers retail and pharmacy, and healthcare services across the United States, Europe, and Latin America.

Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Walgreens Boots Alliance, Inc. (WBA)

Super Micro Computer

Super Micro Computer Inc (NASDAQ: SMCI) will replace Walgreens Boots Alliance Inc (NASDAQ: WBA) in the Nasdaq 100 on July 22nd, as per a press release on Monday. The Nasdaq 100 is an index comprising the largest 100 nonfinancial companies in the Nasdaq Composite.

Supermicro to replace Walgreens in Nasdaq 100: ‘SMCI is an adjacency to NVDA'

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Stakeholders Of Walgreens Boots Alliance Inc To Join The Investigation Of Suspected Securities Fraud

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024. Walgreens describes itself as a “global company that delivers retail and pharmacy, and healthcare services across the United States, Europe, and Latin America.” For more information, submit a form, email attorney Phillip Kim, or give us.

Rosen Law Firm Urges Walgreens Boots Alliance, Inc. (NASDAQ: WBA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased securities of Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, inclusive (the “Class Period”).

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Walgreens Boots Alliance, Inc. (WBA)

NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Shareholders to Contact the Firm!

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Walgreens business and prospects, resulting in its stock trading at inflated prices.

WBA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Walgreens Boots Alliance is planning to scale down its operations. Its major growth campaign looks to be stalled, at least for now.

3 Things You Need to Know if You Buy Walgreens Boots Alliance Stock Today

NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Shareholders to Contact the Firm!

Lululemon Athletica

Markets are testing all-time highs, but not every stock is performing well. One of these stocks looks like the market's best bargain right now.

Is It Time to Buy 2024's Worst-Performing S&P 500 Stocks?

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Walgreens Stock (WBA)